Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial

Nonalcoholic fatty liver disease (NAFLD) is an obesity-related disorder that is rapidly increasing in incidence and is considered the hepatic manifestation of the metabolic syndrome. The gut microbiome plays a role in metabolism and maintaining gut barrier integrity. Studies have found differences i...

Full description

Saved in:
Bibliographic Details
Published in:The American journal of gastroenterology Vol. 115; no. 7; pp. 1055 - 1065
Main Authors: Craven, Laura, Rahman, Adam, Nair Parvathy, Seema, Beaton, Melanie, Silverman, Justin, Qumosani, Karim, Hramiak, Irene, Hegele, Rob, Joy, Tisha, Meddings, Jon, Urquhart, Brad, Harvie, Ruth, McKenzie, Charles, Summers, Kelly, Reid, Gregor, Burton, Jeremy P., Silverman, Michael
Format: Journal Article
Language:English
Published: United States Wolters Kluwer 01.07.2020
Wolters Kluwer Health Medical Research, Lippincott Williams & Wilkins
Subjects:
Apolipoproteins
Bacteria
Cholesterol
Diabetes
Fatty liver
Feces
Gastroenterology
Gastrointestinal surgery
Hypertension
Hypotheses
Insulin resistance
Liver diseases
Metabolic syndrome
Metabolites
Microbiota
Obesity
Patients
Permeability
Transplants & implants
Urine
ISSN:0002-9270, 1572-0241, 1572-0241
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Nonalcoholic fatty liver disease (NAFLD) is an obesity-related disorder that is rapidly increasing in incidence and is considered the hepatic manifestation of the metabolic syndrome. The gut microbiome plays a role in metabolism and maintaining gut barrier integrity. Studies have found differences in the microbiota between NAFLD and healthy patients and increased intestinal permeability in patients with NAFLD. Fecal microbiota transplantation (FMT) can be used to alter the gut microbiome. It was hypothesized that an FMT from a thin and healthy donor given to patients with NAFLD would improve insulin resistance (IR), hepatic proton density fat fraction (PDFF), and intestinal permeability. Twenty-one patients with NAFLD were recruited and randomized in a ratio of 3:1 to either an allogenic (n = 15) or an autologous (n = 6) FMT delivered by using an endoscope to the distal duodenum. IR was calculated by HOMA-IR, hepatic PDFF was measured by MRI, and intestinal permeability was tested using the lactulose:mannitol urine test. Additional markers of metabolic syndrome and the gut microbiota were examined. Patient visits occurred at baseline, 2, 6 weeks, and 6 months post-FMT. There were no significant changes in HOMA-IR or hepatic PDFF in patients who received the allogenic or autologous FMT. Allogenic FMT patients with elevated small intestinal permeability (>0.025 lactulose:mannitol, n = 7) at baseline had a significant reduction 6 weeks after allogenic FMT. FMT did not improve IR as measured by HOMA-IR or hepatic PDFF but did have the potential to reduce small intestinal permeability in patients with NAFLD.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
ISSN:0002-9270
1572-0241
1572-0241
DOI:10.14309/ajg.0000000000000661